Molecular profiling of the Basal-like intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer.

Genome Med · 2025 · PMC12667147 · PMID 41327380

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For both treatment groups, patients with ERpHER2n-Basal tumors showed a trend towards early recurrences (Fig. 1 D-E).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.